Affordable Access

Access to the full text

Evaluation of E. coli Nissle1917 derived metabolites in modulating key mediator genes of the TLR signaling pathway

Authors
  • Damoogh, Sheyda1
  • Vosough, Mehrad2
  • Hadifar, Shima3
  • Rasoli, Masoumeh1
  • Gorjipour, Ali4
  • Falsafi, Sarvenaz1
  • Behrouzi, Ava1, 3
  • 1 Tehran Medical Science, Islamic Azad University, Tehran, Iran , Tehran (Iran)
  • 2 Nourdanesh Institute of Higher Education, Isfahan, Iran , Isfahan (Iran)
  • 3 Pasteur Institute of Iran, Tehran, Iran , Tehran (Iran)
  • 4 Sapienza University of Rome, Rome, Italy , Rome (Italy)
Type
Published Article
Journal
BMC Research Notes
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Apr 26, 2021
Volume
14
Issue
1
Identifiers
DOI: 10.1186/s13104-021-05568-x
Source
Springer Nature
Keywords
License
Green

Abstract

ObjectiveGut-microbiota plays key roles in many aspects like the health and illness of humans. It's well proved that modification of gut microbiota by probiotics is useful for improving inflammatory bowel disease (IBD) conditions. According to recent studies, different types of bacterial metabolites can affect immune cells and inflammation conditions. The present study aimed to evaluate the anti-inflammatory effects of metabolites of E. coli Nissle1917.ResultsThe cell-free supernatant could modulate TNF-α production and affected many crucial mediators in the Toll-like receptor (TLR) signaling pathway. Also, supernatant showed significant dose-dependent properties in this regard. In this study, the TLR signaling pathway was found among probable mechanisms by which probiotics can affect inflammatory situations. These findings provide additional evidence on the use of probiotic metabolites for inhibiting and down-regulating numerous key mediator factors in the TLR signaling pathway. Aberrant or dysfunctional TLR signaling contributes to the development of acute and chronic intestinal inflammatory pathways in IBD. Therefore, finding a component that can affect this process might be considered for therapeutic targets in IBD patients.

Report this publication

Statistics

Seen <100 times